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The iscom as an antigen-presenting structure 
Extensive studies on fundamental mechanisms of 
protection induced by vaccination have led to insight 
into the components necessary for the induction of 
protective immunity. This has enabled vaccine 
researchers to focus on those components which are 
involved in the actual induction of immune responses 
and to exclude irrelevant, immunosuppressive or 
potentially harmful components from vaccines. 
The “ideal” vaccine should meet the following 
requirements: the induction of a long-lasting anti- 
body response of biologically active antibodies, which 
should be elicited even in the presence of maternal 
antibodies ; functional T-cell responses which com- 
prise both major histocompatibility complex (MHC) 
class-I- and class-II-restricted cytotoxic T cells (CTL) 
and helper T cells ; long-lasting protection against in- 
fection with the pathogen. Furthermore, the produc- 
tion procedures must be suitable for large-scale 
production and the product must be stable during 
prolonged periods of storage and transport. Last but 
not least, it has to be safe and devoid of any undesira- 
ble side effects. New generations of vaccines will 
probably be composed of relevant antigen subunits 
either derived from the pathogen itself or prepared 
via molecular biological or synthetic techniques. 
However, vaccine formulations based on individual 
antigens or subunits bearing one or more B- and 
T-cell epitopes in a monomeric form have a major 
disadvantage : they are usually poorly immunogenic 
as compared to the original inactivated or attenuat- 
ed pathogen. Therefore adjuvants or immune en- 
hancers are needed to elicit the desired immune 
response. In general, adjuvants should contribute to 
the requirements stated above for the “ideal” vac- 
cine. Most adjuvants however, only contribute to 
some of these, and concerns about undesirable side 
effects have largely prohibited their use in registered 
vaccines for humans. 
In our laboratory, we have been especially in- 
terested in evaluating the potential of the immune- 
stimulating complex (iscom) as a carrier for viral 
proteins. 
Iscom was first described in 1984 (Morein et al., 
1984). It is a cage-like structure, usually about 30 to 
40 nm in diameter, composed of glycosides present 
in the adjuvant Quil-A, cholesterol, the immunizing 
(protein) antigen and also, in most cases, phos- 
pholipids. Although similar structures had been ob- 
served before (Horzinek et al., 1973), it was not until 
the work of Morein et al. that their potential as an 
immune-enhancing moiety was recognized. 
Quil-A is a crude extract from the bark of Quil- 
Baja saponaria Molina which has potent adjuvant ac- 
tivity and is widely used as an adjuvant in veterinary 
vaccines. The adjuvant activity is due to the presence 
of a mixture of triterpine glycosides (Dalsgaard, 
1978). 
Although antigens of different origin including 
viruses, bacteria and parasites have been incorporated 
into iscoms (table I), in this review, we will mainly 
address data obtained with iscoms containing viral 
antigens. We will discuss the advantages and disad- 
vantages of using Quil-A or iscoms as adjuvants. Fur- 
thermore, we will postulate a working hypothesis 
with respect to the mechanisms by which the iscom 
exerts its specific adjuvant activity. 
The preparation procedure and structure of the 
iscom have been extensively described earlier 
(Hoglund et al., 1989). Recent studies have generat- 
ed detailed information on the structure of the iscom. 
The typical cage-like structure is formed by Quil- 
A/cholesterol micelles which are held together by 
hydrophobic forces (Ozel et al., 1989). This struc- 
ture is very stable. Iscoms can resist repeated freeze- 
thawing and the structure remains intact upon 
lyophilization. The minimal requirements for the for- 
mation of iscoms have been extensively described 
(Lovgren and Morein, 1988). Quil A is a necessary 
constituent of the iscom structure. The size and mor- 
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Table II. A schematic outline representing the procedures leading to iscom production. 
1. Solubilization of (membrane) proteins by adding detergent e.g. TX-100, MEGA-10, octylglucoside. 
2. Separation of solubilized and non-solubilized proteins. 
3. Addition of Quil-A, cholesterol and phospholipid. 
4a. Removal of detergent by dialysis. 
4b. Removal of detergent by centrifugation on a Quil-A-containing sucrose gradient. 
5. Removal of free Quil-A by centrifugation through a 10 Vo sucrose cushion. 
6. Analysis of iscom formation and quality by: negative contrast electron microscopy, SDS-PAGE, immunob- 
lotting and antigen-specific ELISA. 
phology of an iscom is independent of the protein 
incorporated. In fact, “empty” iscoms can be made 
which solely contain Quil A and cholesterol. This 
cholesterol iscom or iscom matrix is a very rigid and 
uniform structure. The incorporation of amphipat- 
ic oligo- or polypeptides requires the addition of 
phospholipids like phosphatidyl ethanolamine or 
phosphatidyl choline. It is speculated that the incor- 
poration of phospholipids provides the flexibility 
necessary for the incorporation of proteins in the 
structure (Lovgren and Morein, 1988). 
Table II represents a schematic outline of the 
principles used for the formation of iscoms. They are 
formed spontaneously when detergent is removed in 
a controlled fashion from a mixture of cholesterol, 
protein, phospholipid, detergent and Quil-A. Deter- 
gents are generally needed to obtain and keep (mem- 
brane) proteins in a monomeric form. The best results 
with many viral membrane proteins were obtained 
when octylglucoside or MEGA- (decanoyl-N- 
methylglucamide) were used as detergents. The de- 
tergent can be removed in several ways, but dialysis 
and centrifugation on a Quil-A-containing sucrose 
gradient have been used most frequently. The cen- 
trifugation method may be used when a non- 
dialysable detergent like Triton-X100 is used. Iscom 
formation is confirmed by negative contrast electron 
microscopy (fig. 1). Furthermore, iscoms have a well 
defined sedimentation (19 S) constant in a sucrose 
gradient. 
One of the interesting features of iscom technol- 
ogy is the fact that a wide range of proteins can be 
incorporated in the structure. Most viral membrane 
proteins are spontaneously incorporated upon for- 
mation of the iscom structure. For the introduction 
of proteins which do not possess membrane inser- 
tion sequences several methods have been developed. 
Pretreatment of hydrophilic proteins, e.g. BSA, by 
adjustment at low pH (2.5), reveals hydrophobic 
Fig. 1. Electron micrograph x 140,000 after negative con- 
trast staining of iscoms which contain measles virus anti- 
gens showing the typical cage-like structure. 
regions normally hidden inside the protein structure 
and allows these regions to interact with the iscom 
matrix (Morein et al., 1990). Palmitification of pro- 
teins, the coupling by overnight incubation with 
palmitoyloxy-succinimide, prior to iscom formation, 
is also used to enable the incorporation of non- 
membrane proteins. The immune response against 
ovalbumin iscoms prepared in this way proved to be 
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as expected for iscoms (Mowat et al., 1991a). The 
acid treatment may be harmful especially to certain 
conformation-dependent epitopes. The water-soluble 
nucleoprotein (NP) of influenza virus was chemical- 
ly linked to bacterial lipopolysaccharide which ena- 
bled its subsequent incorporation in the iscom 
structure (Weiss et al., 1990). 
So far only limited data are available on the in- 
corporation of peptides into iscom and the im- 
munogenicity of such iscoms, although many studies 
are presently being carried out in this area (K. Lov- 
gren, personal communication). It was shown that 
the response against a peptide based on the foot-and- 
mouth disease virus amino acid sequence which was 
coupled to preformed influenza virus iscoms did not 
induce very high anti-peptide antibody titres (Lov- 
gren et al., 1987). Using recombinant DNA tech- 
niques, a Plasmodium falciparum antigen sequence 
was produced as a fusion protein in Escherichia coli. 
When coupled to influenza virus iscoms, this anti- 
gen was shown to be immunogenic in rabbits 
(Sjolander et al., 1991). 
Protective immune responses against viruses induced 
by iscoms 
Herpesviridae 
Viruses which belong to the Herpesviridae fami- 
ly are important pathogens which can establish acute 
and latent infections in many animal species includ- 
ing man. Both humoral and cellular immunity are 
considered important for protection against infection 
with these viruses. Herpes simplex virus 1 (HSVl) and 
2 (HSV2) are members of the Alphaherpesvirinae 
subfamily which infect man. Iscoms have been pre- 
pared with membrane proteins of these viruses and 
tested for their immunogenicity and protective poten- 
tial. Mice generated significant antibody titres after 
immunization with HSVl iscoms and were protect- 
ed against a lethal challenge with HSVl and HSV2 
after a single immunization with 5 pg HSVl iscom 
(Erturk et al., 1989). 
Pseudorabies virus (PrV), another member of the 
Alphaherpesvirinae subfamily, causes disease and 
death in piglets. The selective incorporation of viral 
proteins in iscoms could be useful to discriminate be- 
tween vaccinated and non-vaccinated animals with 
subclinical infection. Iscoms containing the gI1 
glycoprotein of PrV induced complement-dependent 
virus-neutralizing antibodies in mice (Tsuda et al., 
1991). A l-kg dose provided partial protection in 
mice. Pigs immunized with 170 kg gI1 iscoms were 
completely protected against lethal challenge. 
Bovine herpes virus type I (BHVl), yet another 
member of this subfamily, is an important pathogen 
in cattle which causes infectious rhinotracheitis and 
maybe responsible for other clinical manifestations. 
Differentiation between vaccinated and infected 
cattle on the basis of serology is possible when 
subunit vaccines are used that selectively incorpo- 
rate certain proteins. Iscoms containing the enve- 
lope glycoproteins of BHVl were shown to be 
immunogenic in rabbits (Trudel et al., 1987) and 
calves (Trudel et al., 1988a; Merza et al., 1991a). 
Both species developed virus-neutralizing and 
haemagglutination-inhibiting antibodies. Calves 
vaccinated with either 50 or 100 pg BHVl iscoms 
were protected against challenge with 5 x lo6 
TCID,, BHVl. A control group of animals which 
had received a commercial inactivated vaccine proved 
to be unprotected against viraemia in the same 
experiment (Merza et al., 1991b). 
Infection with cytomegaloviruses (CMV), which 
belong to the subfamily Betaherpesvirinae, results in 
the establishment of latent infections in many spe- 
cies that may eventually lead to serious complications 
in immunocompromized hosts. Monkeys which were 
immunized with either CMV-infected monocytes or 
CMV iscoms developed anti-CMV antibody titres 
(Wahren et al., 1987). Cellular responses, measured 
in lymphocyte stimulation tests (LST), were of simi- 
lar magnitude in both groups. Less antigen (15 pg) 
was needed when CMV iscoms were administered in- 
tradermally. However, 150 pg of free unadjuvanted 
CMV nucleocapsid invoked poor cellular responses. 
No protection studies were carried out in this study. 
Epstein Barr virus (EBV), belonging to the sub- 
family Gammaherpesvirinae, infects man and is the 
causative agent of infectious mononucleosis in indus- 
trialized countries. In certain developing countries it 
is associated with the development of undifferentiat- 
ed nasopharyngeal carcinoma and Burkitt’s lympho- 
ma. Cottontop tamarin monkeys (Saguinus Oedipus) 
develop tumours after infection with a high dose of 
EBV. Iscoms containing the EBV glycoprotein gp340 
induced virus-neutralizing antibodies. A 5-pg dose of 
gp340 iscoms given 3 times protected the monkeys 
completely from tumour development (Morgan et al., 
1988). Human T cells from EBV-seropositive donors 
could be stimulated in vitro with gp340 iscoms 
(Ulaeto et al., 1988). 
Hepatitis B virus 
Hepatitis B virus (HBV), a member of the Hepad- 
naviridae family, causes a chronic infection in man 
which may eventually lead to the development of 
primary liver cancer. The first generation vaccines 
consisted of hepatitis B surface antigen (HBsAg) par- 
ticles (20 nm) purified from plasma of infected 
donors. Recombinant DNA techniques have made it 
possible to produce HBsAg particles in yeast cells 
(McAleer et al., 1984). Alum was required as an ad- 
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juvant to enhance immunogenicity of these particles. 
Immunization of mice with iscoms containing HBsAg 
derived from yeast generated high levels of HBV- 
specific antibodies (Howard et al., 1987). 
Rubella virus 
Infection with rubella virus, a member of the fa- 
mily Togaviridae, may cause a mild morbilliform 
rash, occasional fever, and a rather predictable lym- 
phadenopathy in man. Since infection during preg- 
nancy leads to neonatal malformations, vaccination 
during childhood is widely practiced. A live attenu- 
ated rubella virus is used for vaccination worldwide. 
Iscoms containing the El glycoprotein (haemagglu- 
tinin) and the nucleoprotein of rubella virus have 
been prepared. Humoral immune responses in rabbits 
were as high as those observed with a commercial 
live-virus vaccine. The presence of virus-neutralizing 
and haemagglutination-inhibiting antibodies was 
demonstrated. Small amounts of the viral nucleo- 
protein were present in these iscoms which may be 
beneficial for the development of cellular immunity 
(Trudel et al., 1989b). 
Bovine virus diarrhoea virus (BVDV) 
BVDV a member of the Flaviviridae family, 
usually causes subclinical infections in sheep and cat- 
tle. Vertical transmission of the virus may lead to 
abortion and teratogenic defects. Lectin affinity- 
purified BVDV proteins were incorporated in iscoms. 
Pregnant sheep were given two 50-kg doses of BVDV 
iscoms. All animals developed anti-BVDV antibod- 
ies with neutralizing activity. Significant protection 
was observed against a challenge of the sheep with 
BVDV. Some 26 lambs out of 29 were born in the 
vaccinated group whereas only 5 lambs out of 
26 foetuses were born in the non-vaccinated animals 
(Carlsson et al., 1991). 
Paramyxo viridae 
The potential of iscoms for the development of 
subunit vaccines against members of the genus mor- 
billivirus has been explored in our laboratory. Whole 
measles virus iscoms, which contain the fusion pro- 
tein (F) and minor amounts of the haemagglutinin 
protein (H), induced virus-neutralizing, haemag- 
glutination-inhibiting and fusion-inhibiting antibod- 
ies. Iscoms containing immuno-affinity-purified F 
(F-iscom) induced antibodies with haemolysis inhi- 
bition (HLI) activity but devoid of VN activity. Both 
F and H iscom preparations induced protection 
against intracerebral challenge with a rodent-adapted 
measles virus strain (De Vries et al., 1988a ; Varsanyi 
et al., 1987). Immunization with F-iscom induced a 
measles-virus-specific cellular response, delayed type 
hypersensitivity (DTH) and measles-virus-specific 
T-cell clones could be generated from these mice (De 
Vries et al., 1988a). MV iscom also induced humoral 
(in monkey) and cellular (in mice) immune responses 
in the presence of passively transferred antibodies, 
a situation that mimics vaccination in the presence 
of maternal antibodies (De Vries et al., 1990). 
Canine distemper virus (CDV) is a morbillivirus 
closely related to measles virus that causes a disease 
in dogs with a pathogenesis similar to measles in man. 
CDV iscoms were shown to protect dogs against 
viraemia and clinical signs upon intranasal challenge 
with a virulent strain of the virus (De Vries et al., 
1988b). 
CDV iscoms were also used to vaccinate seals 
against phocoid distemper virus (PDV), a recently 
discovered morbillivirus that caused mass mortality 
among seals in the North Sea in 1988 (Osterhaus et 
al., 1989b; Visser et al., 1989). Vaccination was suc- 
cessful since all animals developed PDV-neutralizing 
antibodies. Upon challenge with PDV, vaccinated 
animals were protected whereas two sham-vaccinated 
animals developed clinical signs and died. 
Respiratory syncytial virus (RSV) is another 
Paramyxovirus which causes severe lower respirato- 
ry tract infections in man and cows. Guinea pigs im- 
munized with iscoms based on human or bovine RSV 
developed cross-neutralizing antibody titres. In mice, 
intramuscular immunization with RSV-iscoms in- 
duced virus-neutralizing antibodies, CTL activity and 
protection against virus challenge (Trudel et al., 
1989; Trudel et al., 1992). 
Rabies virus 
Rabies virus belongs to the Rhabdoviridae fami- 
ly and causes fatal disease in warmblooded animals. 
Most currently used vaccines against rabies virus are 
inactivated viruses which are used for pre- and post- 
exposure treatment of rabies infection. Rabies virus 
iscoms prepared from whole purified virus were 
among the first iscoms described (Morein et al., 
1984). In vitro experiments showed that human 
CD4+ T-cell clones could be stimulated with these 
iscoms. Moreover, in vitro stimulation of human 
peripheral blood lymphocytes with rabies virus is- 
corns led to the production of virus-neutralizing an- 
tibodies. Immunization of mice with rabies virus 
iscoms induces a DTH response and neutralizing an- 
tibody titres (Hoglund et al., 1989). In our labora- 
tory, we have generated data which show that both 
MHC class-I- and class-II-restricted T-cell responses 
can be generated after immunization of mice with ra- 
bies virus (Claassen et al., submitted). Iscoms which 
contain lentil-lectin-purified rabies virus glycoprotein 
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were shown to be immunogenic in both mice and 
dogs. These iscoms could protect dogs against a lethal 
challenge with street rabies virus after pre-exposure 
immunization. Moreover post-exposure protection 
against street rabies virus challenge could be induced 
with three 120-ng doses of rabies virus glycoprotein 
iscom in 90 070 of mice but not with three doses of 
a widely used human diploid cell vaccine (HDCV). 
When mice were given four doses of HDCV for post- 
exposure treatment they died of anaphylactic shock. 
No such phenomenon was observed when the mice 
had been immunized with the iscom preparation 
(Fedaku et al., 1992). 
Influenza virus 
Influenza viruses (family Orthomyxoviridae) 
primarily infect the respiratory tract of many animal 
species. Therefore, local immune responses in the 
lung are considered important for protection. The 
two membrane proteins important for eliciting pro- 
tective immune responses are haemagglutinin (HA) 
and neuraminidase (NA). The HA molecule is sub- 
ject to antigenic drift which interferes with the pro- 
tection elicited by vaccines based on the relevant 
strains. Cross-reactive cellular immune responses 
rapidly reduce virus titres in the lung and are there- 
fore considered important. 
Intranasal immunization of mice with two doses 
of 5-pg HANA iscoms elicited antibody titres (IgM, 
IgG and IgA) comparable to those elicited by virus 
infection (Jones et al., 1988 and Lovgren, 1988). Fur- 
thermore, virus-specific antibody-secreting cells could 
be demonstrated in the lungs. In contrast, the same 
dose of HANA micelles induced lower responses of 
mainly IgM antibodies and no local B-cell memory. 
Serum antibody responses could also be demonstrat- 
ed in guinea pigs and horses (Sundquist et al., 1988). 
Both iscoms and micelles induced CTL precursors in 
the lungs of mice but the levels were four-fold higher 
in iscom-immunized mice. Natural killer cells were 
found in similar quantities after immunization with 
either of the antigen preparations (Jones et al., 1988). 
Complete protection of mice against intranasal 
challenge with influenza virus could be induced by 
intranasal and subcutaneous immunizations with 
HANA iscoms (Sundquist et al., 1988 and Lovgren 
et al., 1990). Iscoms containing the influenza 
nucleoprotein induced virus-specific antibody titres 
but no specific CTL responses were observed. About 
50 % of the immunized mice survived challenge with 
a virulent mouse-adapted strain (Weiss et al., 1990). 
Retroviridae 
Iscoms containing the gp70/85 envelope protein 
of feline leukaemia virus (FeLV), a type C virus of 
the Retroviridae family, can induce protection in cats. 
Antibody responses as determined by ELISA, im- 
munofluorescence, virus neutralization and Western 
blotting showed that over 80 % of iscom-immunized 
cats responded compared to only 6 070 of a roup of 
cats vaccinated with a commercial vaccine ( A erblom 
et al., 1989; Osterhaus et al., 1985 and 1989a). 
Iscoms containing gp51 of bovine leukaemia vi- 
rus (BLV, HTLV/BLV group) induced good hu- 
moral immune responses in mice and calves (Merza 
et al., 199la). In calves, neutralizing antibodies could 
be measured after the second inoculation. These 
results showed the potential of iscoms for retrovirus 
vaccine development. 
Human immunodeficiency virus type 1 (HIVl) 
(subfamily Lentivirinae) is the causative agent of 
AIDS in man. Until now, no safe and effective vac- 
cines against this disease are available. The develop- 
ment of a suitable vaccine is hampered by the 
variability of the viral envelope protein gpl20 which 
induces neutralizing antibodies. Multiple injections 
in rhesus monkeys with iscoms containing gpl20 of 
HIV1 induced ten-fold higher neutralizing titres than 
comparable amounts of gpl20 with an alum adju- 
vant (Pyle et al., 1989). In mice, a 5-ug dose of these 
gpl20 iscoms induced two-fold higher titres when 
compared with a 5Oyg dose of gpl20 in complete 
Freunds’ adjuvant. Sera from rhesus monkeys 
(Macaca mulatta) cross-neutralized RF and MN iso- 
lates of HIV. The induction of class-I-restricted 
precursor CTL in mice was demonstrated using 
gpl60-iscom-immunized mice. Spleen cells obtained 
from these mice could kill target cells expressing HIV 
gpl60 or pulsed with a known immunodominant 
CTL peptide (Takahashi et al., 1990). 
Several animal models exist to study the immu- 
nity and pathogenesis of HIV-related viruses. Simian 
immunodeficiency virus (SIV) is a closely related len- 
tivirus which can infect rhesus macaques and cause 
an AIDS-like syndrome. In a recent study from our 
laboratory, it was demonstrated that a SIV-iscom 
preparation as well as whole inactivated SIV ad- 
juvanted with muramyl dipeptide (MDP) could pro- 
tect animals against an intravenous homologous 
challenge with 10 MID,, of cell-free SIV. All 
animals were protected from developing SIV-specific 
viraemia for at least a twelve-week period after 
challenge. Fifty percent of the vaccinated animals in 
a similar experiment were also protected for at least 
nine weeks against an intravenous challenge with 
SIV-infected peripheral blood mononuclear lympho- 
cytes (Osterhaus et al., 1992). In another study, 
cynomolgus monkeys (Macaca fascicularis) were in- 
fected with HIV2 after immunization with 
HIVZiscoms or inactivated HIV2 with complete 
Freund’s adjuvant (CFA) (Putkonen et al., 1991) 
HIV2-iscom-immunized monkeys were not protect- 
ed against infection with HIV2 which was probably 
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due to the virtual absence of gp125 in the iscom 
preparation used. These results demonstrate that vac- 
cination against lentivirus infections should not be 
considered impossible. 
General considerations for the use of iscoms 
as an antigen-presenting moiety 
Mode of administration 
Iscom preparations have generally been ad- 
ministered intramuscularly or subcutaneously. Only 
small amounts - 1 to 10 pg - of incorporated an- 
tigens are needed to elicit effective immune responses 
in mice. It was found that the time between first and 
second immunization is critical for the development 
of a booster response. An interval between 6 to 
8 weeks seems optimal to elicit a booster effect (Lov- 
gren et al., 1990). Short immunization protocols like 
the NIH efficacy test for rabies vaccines, in which 
case the interval is only one week, give lower titres 
and protection levels. One intraperitoneal immuni- 
zation of mice with 360 ng of rabies virus 
glycoprotein iscom is sufficient to protect almost 
90 % against intracerebral challenge with rabies vi- 
rus (Fedaku et al., 1992). 
Recently the use of iscoms for oral immunization 
was also investigated. Attempts to investigate the pos- 
sibility of oral immunization were undertaken with 
influenza virus iscoms but these were largely unsuc- 
cessful, probably because the administered antigen 
dose was too low, i.e. 5 pg (Lovgren, 1988). No sys- 
temic antibody response could be measured and it 
was speculated that iscoms could not resist degrada- 
tion in the gastrointestinal tract. Intranasal immu- 
nization with influenza virus iscoms, however, led to 
a specific antibody response of all classes and sub- 
classes, including IgA, and also to cellular responses 
in the lung (Jones et a/., 1988). This showed that lo- 
cal immunization with iscoms may lead to the induc- 
tion of both local and systemic immune responses. 
Ovalbumin(OVA)-containing iscoms were shown to 
be immunogenic after systemic but also after oral im- 
munization (Mowat et al., 1991). Oral immunization 
with OVA iscom induced specific serum antibodies. 
Cellular responses were measured by DTH response. 
The required dose for oral immunization was 
10 times higher (100 pg) than that needed for paren- 
teral immunization, which is probably due to par- 
tial degradation of the immunogen in the 
gastrointestinal tract before iscoms can reach im- 
munocompetent cells or lymphoid organs in the gut. 
Repeated feeding with OVA-iscom induced MHC 
class-I-restricted CTL specific for OVA (Mowat et 
al., 1991). When soluble OVA was given orally 
in comparable amounts no responses could be 
measured. 
Secretory immune responses in the vagina of mice 
could be measured after intraperitoneal, subcutane- 
ous or intravaginal immunization with iscom contain- 
ing sheep red blood cell (SRBC) membrane antigens. 
Non-mucosal immunization in the pelvis induced 
higher systemic and local titres than local applica- 
tion, and local application required 10 times higher 
amounts of antigen (Thapar et al., 1991). 
The finding that iscom can be used for local im- 
munization is important for the development of pro- 
tection against pathogens which acquire access 
through mucosal membranes and therefore require 
musocal immunity. The importance of the mucosal 
immune system for vaccine development has recent- 
ly been reviewed (McGhee el al., 1992). 
Toxicological aspects 
When iscoms are considered as vaccine candidates 
for humans, toxicological aspects of the incorporat- 
ed adjuvant Quil-A should be considered. So far, one 
study has been published on the in vivo effects of 
Quil-A-containing iscoms after intramuscular injec- 
tion (Speijers et al., 1988). Only a moderate inflam- 
matory reaction was observed in 1 out of 6 rats which 
had received an iscom dose containing 60 pg Quil-A. 
It should be noted that the haemolytic activity of 
Quil-A incorporated in iscom is ten times lower than 
observed with free Quil-A (Kersten, 1991). 
Attempts have been made to separate the in- 
dividual components of Quil-A in order to segregate 
the haemolytic and adjuvant activity (Kensil et al., 
1991; Kersten, 1991). Kensil described the separation 
by reverse-phase HPLC of Quil-A into 4 fractions 
which all retained their adjuvant activity. One frac- 
tion (QS-7) showed no direct lethal effect in mice at 
a dose of 500 pg. Unfortunately this fraction was not 
tested for its ability to form iscoms. Kersten, using 
the same approach, reported the separation of Quil-A 
into 23 fractions. Six of these purified saponins could 
be used to form iscom-like particles of varying size, 
but these were consistently larger than iscoms pre- 
pared from unpurified Quil-A. Immunogenicity 
studies were performed using iscom with the 
gonococcal PI protein incorporated. Iscoms made 
with the so-called fraction QA-3 were as immuno- 
genic as total Quil-A iscoms. The haemolytic activi- 
ty of QA-3 was 15 times reduced as compared to total 
Quil-A. Since the mean size of QA-3-iscoms is 
between 110 and 145 nm, the influence of particle 
size on immunogenicity has to be evaluated. 
It should be noted that no negative side effects 
have been observed with the use of an iscom-based 
commercial equine influenza vaccines in horses 
(Sundquist et al., 1988), or with any other iscom 
preparation (Nagy ef al., 1990). Moreover, Quil-A 
is accepted in veterinary vaccine preparations for pigs 
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and cows at 10 to 100 milligram doses, about lOO- 
to l,OOO-fold higher than that used in iscom prepa- 
rations. Nevertheless, before iscom can be used in 
vaccines for human application, further toxicologi- 
cal studies are needed. These studies should focus on 
iscoms and their individual components and should 
deal with acute and subacute toxicity as well as pos- 
sible mutagenic effects and sensitization. This may 
be omitted for iscom administered orally since sapo- 
nins are accepted food additives. 
How do iscoms work ? 
The quantitative and qualitative effects on the im- 
mune responses as found after iscom immunization 
raise the question as to what determines the im- 
munogenicity of the iscom structure. The higher and, 
in some cases, longer persisting antibody titres can 
easily be explained if one assumes that incorporated 
Quil-A retains its normal adjuvant activity. It has 
been suggested that the retention time of the im- 
munizing antigen at the injection site and the uptake 
amount in the lymphoid organs, as observed with in- 
fluenza iscoms (Watson et al., 1989) and with Quil-A 
as adjuvant (Scott et al., 1985) may be important for 
the observed effects. However, when Quil-A was 
used as adjuvant, the inflammatory reaction and an- 
tigen retention could be completely inhibited by the 
addition of cholesterol without affecting adjuvant ac- 
tivity (Scott et al., 1985). A progressive redistribu- 
tion of iscom-bound radioactive labelled antigen to 
the spleen was observed when compared to antigen 
in micelles (Watson et al., 1989). Furthermore, we 
have recently observed that iscoms in vivo are taken 
up in mice by a distinct subset of macrophages in the 
spleen which is not involved in the uptake of free in- 
activated antigen (Claassen et al., submitted). 
Furthermore, the multimeric presentation form 
of the incorporated proteins and the presence of 
Quil-A in the same unique structure proved to be es- 
sential for the observed effects. Using different bio- 
tin/protein ratios, it was shown that at least 3 biotin 
molecules have to be coupled to a preformed iscom 
to induce an antibody response 10 times higher than 
that achieved when only one biotin molecule is cou- 
pled (Lovgren et al., 1987). This finding clearly il- 
lustrates that the multimeric form is important for 
the observed adjuvant activity of the iscom structure. 
Although speculative, this might also be necessary 
for the induction of MHC class-I-restricted CTL, 
even when proteins like OVA, which are normally 
not immunogenic for these T cells are included. It 
is generally accepted that at least two distinct routes 
exist for the degradation of foreign antigen and the 
presentation different subsets of T cells (Yewdell and 
Bennink, 1990). First, the uptake of antigens into 
lysosomes, which leads to the degradation of foreign 
proteins and to the formation of peptides which then 
associate with MHC class II molecules and are recog- 
nized by T cells bearing the CD4 marker. Secondly, 
the cytosolic processing pathway into which enter 
proteins which are synthesized in the cytosol, released 
into the cytosol by lysis of endosomes or by antigens 
penetrating through the plasma or endosomal mem- 
branes. This pathway generates peptides that associ- 
ate with MHC class I molecules which are recognized 
by CD8+ T cells. In general, non-replicating anti- 
gens do not enter the cytosolic pathway, so that no 
priming for MHC class-I-restricted CTL occurs. The 
ability of iscoms to stimulate CDS+ CTL in vivo has 
been demonstrated with different iscom preparations 
(Jones et al., 1988; Takahashi et al., 1990; Mowat 
et al., 1991 ; Trudel et al., 1992), even after oral im- 
munization (Mowat and Donachi, 1991). In our 
laboratory, data have been generated which show 
that iscoms can stimulate MHC class-I-specific CTL 
in vitro (van Binnendijk et al., submitted) and in vivo 
(Claassen et al., submitted). The in vitro stimulation 
of measles-virus-specific CTL is dependent on the 
presence of MHC class-I-matched antigen-presenting 
cells. It may thus be hypothesized that at least in vitro 
iscoms are able to enter the cytosolic processing path- 
way which leads to expression of peptides in the con- 
text of MHC class 1 molecules. Iscoms could act as 
a carrier enabling proteins to penetrate the plasma 
and endosomal membranes partially or entirely, thus 
exposing iscom-bound protein to both proteolytic 
compartments. Perhaps iscoms are not only taken up 
by APC to enter the lysosomal compartment but they 
may also pass through or into the membrane of the 
cells, meanwhile protecting the protein for proteo- 
lytic degradation, and thus exposing the protein to 
cytoplasmic proteases. Intact and partially degrad- 
ed iscoms could be demonstrated attached to mac- 
rophage cell membranes and within phagosomal 
membranes in close association with phagosomal 
membranes but not in the cytoplasm (Watson et al., 
1989). 
The proposed capability of iscom to pass into the 
membrane may be explained by their hydrophobic 
structure, and because they contain saponins which 
can intercalate into cholesterol membranes (ijzel el 
al., 1989). This in fact determines the haemolytic 
properties of Quil-A. Iscoms are extremely stable 
structures and thus may be able to pass through cell 
or lysosomal membranes and so enter the cytosolic 
processing pathway thereby stimulating CD8+ CTL. 
Conclusion 
In summary, we conclude that the iscom matrix 
is a promising moiety for the presentation of anti- 
gen to the immune system. It lacks many of the dis- 
advantages of traditional live vaccines as regards 
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safety. The major points in favour of an iscom ap- 
proach to developing new vaccines are the follow- 
ing : they generate long-lasting biologically functional 
antibody responses ; they generate immunological 
responses in the presence of maternal antibodies ; 
they generate functional cell-mediated immune 
responses ; they generate protection in several sys- 
tems. However, before iscom technology can be ap- 
plied to the production of vaccines for human use 
the toxicity of individual iscom preparations will have 
to be studied and documented in more detail. Since 
there is an urgent need for new generations of vac- 
cines, especially against viral infections like HIVI, 
EBV and RSV, the further development of the iscom 
as an immune-enhancing moiety deserves more at- 
tention. 
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Introduction 
Liposomes are artificially prepared spheres com- 
posed of concentric phospholipid bilayers, separat- 
ed by aqueous compartments. Hydrophobic 
interactions of the phospholipids are the driving force 
of formation of liposomes when phospholipids are 
confronted with water. Liposomes may differ in their 
dimension, composition (different phospholipid and 
cholesterol content), charge (resulting from the 
charges of the component phospholipids), and struc- 
ture (multi- vs unilamellar). These physical proper- 
ties and the location of antigens in liposomes 
determine the adjuvanticity of the liposome. 
There are a number of important advantages of 
liposomes when used as immunoadjuvant : they are 
biodegradable, nontoxic, immunologically inert, sim- 
ple to prepare and their composition can be varied 
to obtain the most efficient antigen-liposome prepa- 
ration. In combination with other immunoadjuvants, 
liposomes may induce an extremely strong immune 
response. 
The toxicity of certain antigens can be reduced 
by their incorporation into liposomes, and liposomes 
can be used to modulate the immune response 
(reviewed by Van Rooijen, 1990a). Liposomes have 
the ability to elicit both a cellular mediated immune 
response (CMI; Garcon and Six, 1991) and a hu- 
moral immune response (HI) to antigens ad- 
ministered by a variety of routes, and there is a poten- 
tial for selective interaction with populations of 
immunocompetent cells (Gregoriadis, 1990). In some 
cases, liposomes can be stronger adjuvants than com- 
plete Freund’s adjuvant (CFA; Gregoriadis and Ma- 
nesis, 1980; Brynestad et al., 1990), but when the 
antigens are e.g. immunogenic proteins, the immune 
response is slightly higher when CFA is used as ad- 
juvant (Sanchez et al., 1980; Alving et al., 1986). In- 
clusion of cholesterol or sphingomyelin in liposomes 
increases the stability of their phospholipid bilayers 
and decreases their susceptibility to destruction by 
various serum components (Scherphof et al., 1978 ; 
Kirby et al., 1980; Claassen et al., 1988). Cholester- 
ol inclusion also influences the interaction of lipo- 
somes with lymphoid and non-lymphoid cells 
involved in immune reactions (Van Rooijen and Van 
Nieuwmegen, 1982). 
Immune reaction against liposome-associated 
antigens and haptens 
The use of liposomes as immunoadjuvants was 
first described by Allison and Gregoriadis (1974). 
Since than, many studies have confirmed this capa- 
bility to enhance the immune response to various an- 
tigens (Van Rooijen, 1988). Interest centred on the 
